Mounjaro in Srinagar: Benefits, Risks, Cost and Eligibility

Mounjaro (tirzepatide) has produced weight loss results that medicine had never before achieved without surgery — up to 21% body weight in clinical trials. Here is everything people in Srinagar need to know about benefits, risks, eligibility, and safe access.

What is Mounjaro (tirzepatide)?

Mounjaro is the brand name for tirzepatide — an injectable medication belonging to a class called dual GIP/GLP-1 receptor agonists. It works by activating two hormonal pathways simultaneously: GLP-1, which slows gastric emptying, reduces appetite, and improves insulin secretion; and GIP, which further enhances insulin release and improves insulin sensitivity in fat tissue. By activating both pathways, Mounjaro achieves more powerful metabolic effects than GLP-1-only medications like semaglutide. It is injected once weekly via a pre-filled auto-injector pen under the skin, typically in the abdomen, thigh, or upper arm. Mounjaro is a prescription medication that should only be used under the guidance of a qualified physician. For a broader explanation of how these hormonal mechanisms work, see: What is GLP-1 and why is everyone talking about it?

What the trial data shows

The SURMOUNT clinical trial programme produced results that genuinely surprised the medical community. In SURMOUNT-1, adults with obesity but no diabetes lost an average of 20.9% of their body weight at 72 weeks on the highest dose — equivalent to approximately 21 kg for a 100 kg person. In SURMOUNT-2, which included adults with both obesity and type 2 diabetes, average weight loss was 15.7%. For context, most lifestyle interventions produce 5 to 7 kg of weight loss; previous obesity medications produced 8 to 10% body weight reduction. Beyond weight loss, Mounjaro consistently produced significant reductions in HbA1c, blood pressure, triglycerides, and liver fat. Monitor your blood sugar response to treatment with regular HbA1c testing — available at home in Srinagar.

Who is eligible for Mounjaro?

Based on international regulatory approvals, Mounjaro is indicated for type 2 diabetes management and for chronic weight management in adults with a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidaemia, sleep apnoea, or cardiovascular disease. Mounjaro is not appropriate for people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2, people with type 1 diabetes, pregnant women or those planning pregnancy, those with a history of pancreatitis, or children and adolescents under 18. A thorough medical assessment by a qualified physician is essential before starting. A doctor home visit in Srinagar can conduct this assessment and arrange the appropriate baseline blood tests.

Risks and side effects to know

The most common side effects are gastrointestinal and typically occur during dose escalation: nausea affects approximately 40 to 45% of users, diarrhoea around 25%, vomiting around 20%, and constipation around 15%. These are dose-dependent, usually most pronounced in the first four to eight weeks, and significantly improve as the body adjusts. The gradual dose escalation protocol — starting at 2.5 mg weekly and increasing over several weeks — is specifically designed to minimise them. Serious but less common risks include pancreatitis (characterised by severe persistent abdominal pain — stop medication and seek urgent care); thyroid tumours noted in animal studies (watch for a neck lump, hoarseness, or difficulty swallowing); and gallbladder disease associated with rapid weight loss. Maintaining adequate protein intake and engaging in resistance exercise is strongly recommended during treatment to preserve muscle mass. Physiotherapy services in Srinagar can help design an appropriate programme during treatment.

What happens when you stop Mounjaro?

This is critically important to understand before starting treatment: weight typically returns after stopping Mounjaro. Clinical studies consistently show that most of the weight lost during treatment is regained within one to two years of discontinuation. This means Mounjaro is a long-term treatment for a chronic condition, not a short course — the same principle applies to blood pressure or diabetes medication. Stopping treatment reverses its benefits. This has significant implications for cost and long-term commitment, and must be discussed openly with your physician before starting. The monthly cost in India has ranged from approximately Rs 15,000 to Rs 25,000 depending on dose, which should be weighed against the long-term cost of managing obesity-related complications.

Essential tests before starting Mounjaro in Srinagar

Before beginning Mounjaro, your physician will typically assess: HbA1c and fasting blood sugar to establish a glycaemic baseline; kidney function and liver function as safety baselines; a lipid panel for cardiovascular context; and thyroid function to exclude thyroid cancer history. All blood tests can be arranged for home collection in Srinagar. A doctor home visit can coordinate the full pre-treatment workup without any need for hospital attendance. For a comparison of Mounjaro with semaglutide (Ozempic and Wegovy), see: Mounjaro vs Ozempic — which weight loss treatment is better?.